Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF to Net Income | 100.7% | 57.8% | 48.9% | 52.5% | 405.7% | 11.4% | 182.1% | 98.3% | 69.5% | 225.3% | 90.5% | 51.1% | 84.1% | 92.8% | 100.8% | 277.8% | 135.3% | 100.3% | 91.3% | 75.9% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month FCF to Net Income is 80.8%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for United Therapeutics Corporation have been 95.1% over the past three years, and 129.5% over the past five years.
As of today, United Therapeutics Corporation's FCF to Net Income is 80.8%, which is lower than industry median of 83.9%. It indicates that United Therapeutics Corporation's FCF to Net Income is Bad.